Synthetic ceramides induce apoptotic death of Jurkat and HL60 leukaemia cell lines. By contrast we show here that ceramide induces non-apoptotic killing of malignant cells from patients with B-chronic lymphocytic leukaemia (B-CLL) and of normal B lymphocytes. The protein phosphatase inhibitor okadaic acid readily induces apoptosis of B-CLL cells, indicating that this death pathway is fully functional in these cells. The ability of ceramide to activate the apoptotic protease caspase 3 in HL60 cells but not in B-CLL cells, as well as the lack of correlation of ceramidemediated killing of dierent B-CLL isolates with expression of the apoptosis-regulating proteins bcl-2 and bax reinforce the conclusion that ceramide killing of B-CLL cells is by a non-apoptotic mechanism. Fludarabine treatment or g-irradiation of B-CLL cells resulted in ceramide elevation and in killing by both apoptotic and non-apoptotic mechanisms, suggesting that a ceramide-triggered non-apoptotic mechanism may play a role in the killing of these cells. Therefore, the results here show that ceramide can induce either apoptotic or non-apoptotic death, depending on the cellular context. The inability of synthetic dihydroceramide to kill B-CLL cells or normal B lymphocytes suggests that non-apoptotic killing by ceramide is via interaction with a speci®c, but unidenti®ed, cellular target.
Introduction
Apoptosis is a form of physiological cell death characterized by cell shrinkage, nuclear condensation, DNA fragmentation and eventual phagocytosis. In contrast, necrotic cell death is associated with cell swelling, loss of cytoplasmic electron-opacity and early rupture of the plasma membrane (Kerr et al., 1994) . Apoptosis is dependent on the activation of cellintrinsic pathways by speci®c triggers, including the induction of DNA damage by antineoplastic drugs (Hannun, 1997) .
Induction of apoptosis in response to TNF treatment (Schutze et al., 1992; Jarvis et al., 1994) Fas ligation Chinnaiyan et al., 1996) , irradiation (Haimovitz-Friedman et al., 1994) and cytotoxic drugs (Bose et al., 1995) is preceded by elevation of ceramide levels, usually a consequence of sphingomyelinase activation and the subsequent cleavage of sphingolipids (Hannun, 1996) . The role of ceramide generation in apoptosis induction is emphasized by the observation that lymphoblasts from patients with Niemann-Pick disease, which lack acid sphingomyelinase, fail to undergo radiation-induced apoptosis (Santana et al., 1996) . Radiation-induced apoptosis is also blocked in the lungs of acid sphingomyelinase knockout mice (Santana et al., 1996) .
Synthetic ceramides, but not dihydroceramides, elicit apoptotic responses in cell lines, suggesting that ceramide action is dependent on biochemical interactions of the lipid with speci®c cellular targets (Obeid et al., 1993; Jarvis et al., 1994; Tepper et al., 1995; Chinnaiyan et al., 1996) . Biochemical targets of ceramide include a protein kinase (Zhang et al., 1997) and a protein phosphatase (Wol et al., 1994) . Apoptosis induction by ceramide may involve the activation of speci®c gene expression by c-jun, triggered by the activation of c-jun N-terminal kinase (JNK) in some (Sawai et al., 1995; Westwick et al., 1995; Verheij et al., 1996) but not all (Ohmori et al., 1997) cell types. However, the immediate target of ceramide which is responsible for triggering the apoptotic cascade has not been identi®ed (Susin et al., 1997a) .
Some malignant cells are refractory to the induction of apoptosis as a result of impaired detection of apoptotic signals (Hannun, 1997) . Malignant cells which generate ceramide in response to irradiation are more sensitive to killing than are cells which do not. However, both the radio-resistant and sensitive cells were killed by exogenous ceramide (Wright et al., 1996; Chmura et al., 1997; Michael et al., 1997) . Therefore, direct intevention in later stages of apoptotic signal transduction may facilitate killing of malignant cells which are refractory to conventional therapy (Hannun, 1997) . Because B-chronic lymphocytic leukaemia (B-CLL), the most frequent leukaemia in the western world, is incurable by conventional chemotherapy (Foon et al., 1990) , we have investigated the actions the synthetic ceramide N-acetyl-Derythro-sphingosine (C 2 ceramide) on malignant cells isolated from patients with this disease.
Results
Normal and malignant B lymphoid cells are susceptible to killing by C 2 ceramide Exposure of B-CLL cells to 20 mM C 2 ceramide resulted in their killing as determined by staining with trypan blue or by propidium iodide (PI). We observed a wide variation in the rates of killing of malignant cells isolated from dierent patients (Figure 1 ). Normal tonsillar B cells were also susceptible to killing by C 2 ceramide. The mean percentage of dead cells observed following 6 h incubation with 20 mM C 2 ceramide was 30+5.5% (n=30; range, 2 ± 98%) for cells isolated from a cohort of B-CLL patients and 74+3% (n=8; range 48 ± 98%) for B lymphocytes from normal donors. Therefore, B-CLL cells were less susceptible to killing by C 2 ceramide than were normal B cells (P50.001, Student's t-test).
N-acetyl-D-erythro dihydrosphingosine (C 2 dihydroceramide; 20 mM) either failed to kill both normal and malignant B cells, or did so much less eciently than did C 2 ceramide (Figure 1 ), emphasizing the requirement for the double bond in the sphingosine backbone for optimal activation of the death pathway in these cells.
C 2 ceramide-mediated killing of B lymphoid cells is by a non-apoptotic mechanism
Apoptotic cells show a characteristic reduction in DNA content as determined by FACScan analysis (Naito et al., 1997) . B-CLL cells failed to show a reduction in DNA content following exposure to C 2 ceramide (Figure 2 ), despite the induction of 48% cell killing in this experiment. However, a sub-diploid population was clearly observed in B-CLL cells treated with the protein phosphatase inhibitor okadaic acid, a known inducer of apoptosis (Fernandez-Sanchez et al., 1996) , or subjected to g-radiation (Figure 2 ). By contrast, C 2 ceramide, but not C 2 dihydroceramide, induced a subdiploid population in Jurkat cells. Okadaic acid treatment and g-irradiation of Jurkat cells also induced the generation of cells with a sub-diploid DNA content (Figure 2 ).
Induction of apoptosis was additionally quanti®ed by¯uorescent labelling of nuclei containing DNA strand breaks (TUNEL assay). This analysis con®rmed that C 2 ceramide did not induce signi®cant apoptosis in either B-CLL cells or normal B lymphocytes despite the induction of substantial cell killing (Table 1) . These conclusions were con®rmed by determination of the proportion of apoptotic cells by light microscopic evaluation of giemsa-stained cytospin preparations (data not shown). By contrast, treatment of both Jurkat and HL60 cell lines with C 2 ceramide, but not C 2 dihydroceramide, clearly increased the proportion of apoptotic cells (Table 1) .
Electron microscopic analysis showed that C 2 ceramide-induced rupture of the plasma membrane and the nuclear envelope of B-CLL cells. Nuclear condensation, which is a hallmark of apoptosis, was not observed (Figure 3 , upper row). C 2 ceramide induced similar morphological features in normal B lymphocytes (not shown). By contrast, okadaic acid clearly induced nuclear condensation in a large proportion of B-CLL cells (Figure 3 , lower row), con®rming the ability of this agent to induce apoptotic killing of these cells. The induction of apoptosis following C 2 ceramide treatment of Jurkat cells was also con®rmed by electron microscopy (Figure 4) .
Detailed time-course and dose-response studies were carried out using three dierent B-CLL isolates. C 2 ceramide concentrations between 1 and 100 mM were used and cells were withdrawn at 0, 1, 2, 4 and 6 h for morphological analysis. We failed to observe the Figure 2 FACScan analysis of DNA content of B-CLL and Jurkat cells. Propidium iodide-stained cells were analysed as described in Materials and methods. Synthetic ceramides were added at 20 mM and cells analysed at 5 h. Cells exposed to 20 nM okadaic acid or 10 Gy g-radiation were analysed after 20 h incubation. Cells to the left of the arrow have a sub-diploid DNA content. Similar results were obtained in 14 additional experiments Table 1 Quantitation of cell killing and apoptosis induction in ceramide-treated cells Following 6 h incubation with the indicated additions, the percentage of dead cells (D) was determined by trypan blue staining. The percentage of apoptotic cells was determined by TUNEL assay (T). Synthetic ceramides were added at 20 mM and ZVADfmk at 100 mM induction of apoptosis at any of the concentrations of C 2 ceramide used or at any of the time points studied (data not shown). Therefore, the failure of C 2 ceramide to induce apoptosis of B-CLL cells is not dependent on the concentration used or on the time of analysis.
Killing of B-CLL cells by C 2 ceramide is independent of caspase activation
Apoptotic cell death including that induced by ceramide is dependent on the activation of members of the caspase family of proteases (Salvesen and Dixit, 1997). However, ceramide-mediated killing of two B-CLL isolates, as quantitated by trypan blue staining, was not decreased by the addition of ZVADfmk, a broad speci®city caspase inhibitor (Table 1) .
By contrast, okadaic acid-induced apoptotic nuclear condensation was partially suppressed by ZVADfmk (Figure 3 , panels G and H). The blockade of induction of TUNEL positivity by ZVADfmk was variable in dierent B-CLL isolates (Table 2 and data not shown). Although ZVADfmk decreased the induction of apoptotic morphology by okadaic acid, the cells nevertheless died by a mechanism resembling necrosis. Others have also reported that ZVADfmk blocks the induction of nuclear condensation but does not prevent cell killing in response to multiple signals (McCarthy et al., 1997; Hirsch et al., 1997) . These observations suggest that failure to activate caspases results in a switch in the death pathway, resulting in cell killing by a mechanism resembling necrosis.
ZVADfmk also failed to decrease the overall rate of killing of Jurkat or HL60 cells by C 2 ceramide, but dramatically decreased the induction of apoptosis in these cell lines as detected by TUNEL assay (Table 1) . Electron microscopic analysis of Jurkat cells additionally con®rmed that treatment with ZVADfmk abrogated the induction of nuclear condensation by C 2 ceramide while permitting cell death to occur by necrosis (Figure 4) .
Treatment of B-CLL cells with C 2 ceramide for 4 h failed to augment caspase 3 activity. However, treatment with 20 nM okadaic acid resulted in a ninefold increase in the activity of caspase 3 ( Figure  5 ). C 2 ceramide treatment of three further B-CLL isolates for periods ranging from 1 ± 6 h also failed to increase caspase 3 activity (not shown). In contrast, C 2 ceramide treatment of HL60 cells resulted in an increase in caspase 3 activity, as did treatment with the cytotoxic drug etoposide ( Figure 5 ). None of the treatments depicted in Figure 5 resulted in an increase in activity of caspase 1 in either B-CLL or HL60 cells (not shown), con®rming the speci®city of the caspase assay.
Taken together, these observations suggest that C 2 ceramide induces caspase-dependent apoptotic cell killing in the Jurkat and HL60 cell lines. By contrast, ceramide-induced killing of normal and malignant B lymphocytes occurs by a non-apoptotic mechanism which is independent of caspase activation C 2 ceramide-mediated killing of B-CLL cells is not dependent on protein synthesis
When added alone at concentrations between 1 and 100 mM, the protein synthesis inhibitor cycloheximide did not induce killing of B-CLL cells during a 6 h exposure. Incubation of the cells with 20 mM C 2 ceramide resulted in 480% killing which was not abrogated by cycloheximide, suggesting that ceramideinduced death of B-CLL cells was independent of new protein synthesis. These observations, which were replicated using two additional B-CLL isolates, argue against a role for the activation of speci®c gene expression in the killing of B-CLL cells by C 2 ceramide.
Killing of B-CLL cells by C 2 ceramide does not correlate with the expression of bcl-2 and bax proteins Induction of apoptosis by many stimuli is blocked by the expression of the bcl-2 or bcl-X L proteins, whereas the bax protein enhances susceptibility to cell killing (Yang and Korsmeyer, 1996) . Apoptotic killing of Following 24 h incubation with the indicated additions, the percentage of apoptotic cells was determined by TUNEL assay Figure 3 Electron microscopic analysis of B-CLL cells. Cells were incubated with C 2 ceramide (Cer) for 6 h or with okadaic acid (OA) for 20 h. NA, no addition. The bar represents 2 mm. ZVADfmk was used at 100 mM Figure 4 Electron microscopic analysis of Jurkat cells. NA, no addition, Cer, +20 mM ceramide. Incubations were for 6 h leukaemia cell lines by ceramide is blocked by overexpression of bcl-2 (Zhang et al., 1996; Wiesner et al., 1997 : Susin et al., 1997b Allouche et al., 1997) . However, necrotic death induced by respiratory inhibitors is also sensitive to bcl-2 over-expression (Shimizu et al., 1996) , suggesting that apoptotic and necrotic cell death may share some common regulatory steps.
Because killing of B-CLL cells by cytotoxic agents is compromised by high levels of bcl-2 compared to bax (Thomas et al., 1996; Pepper et al., 1997) , we determined whether ceramide sensitivity of B-CLL isolates was also related to the expression of these proteins. We observed no obvious relationship between the expression of either protein and the extent of cell killing after 6 h treatment with C 2 ceramide (Figure 7 ). Graphical analysis (not shown) also failed to reveal a signi®cant correlation between the ratio of expression of bcl-2 and bax (as determined by densitometric scanning of Western blots) and the rate of cell killing.
Although B-CLL cells express undetectable bcl-X L (Panayiotidis et al., 1995) , we cannot rule out the possibility that other proteins of the bcl-2 family may modulate ceramide sensitivity.
An inhibitor of ceramidase does not abrogate killing of B-CLL cells by C 2 ceramide
Ceramides are hydrolyzed by ceramidases, resulting in the generation of sphingosine. Since sphingosine itself is lethal to some cells, (Pushkareva et al., 1997; Jarvis et al., 1997) , we determined whether B-CLL killing by C 2 ceramide could be due to the generation of sphingosine. Incubation of B-CLL cells with 20 mM sphingosine resulted in the killing of B-CLL cells, although this agent was less eective than C 2 ceramide (Figure 7 ). D-erythro-2 (N-myristoylamino)-1-phenyl-1-propanol (MAPP) is a potent inhibitor of alkaline ceramidase with an IC 50 of 1 ± 3 mM (Bielawska et al., 1996) . Ten micromolar MAPP failed to reduce cell killing by C 2 ceramide (Figure 7 ). Morphological analysis additionally showed that C 2 ceramidemediated killing occurred by a non-apoptotic mechanism both in the presence or absence of MAPP (not shown).
Fludarabine treatment or g-irradiation of B-CLL cells results in ceramide generation
Treatment of an isolate of B-CLL cells with 20 mM udarabine or with 10 Gy g-radiation resulted in a clear increase in cell-associated ceramide levels ( Figure  8 ). Untreated cells contained 19.4 pmol ceramide/10 6 cells, which was increased to 33.7 and 32.8 pmol/10 6 cells 1 h following exposure to¯udarabine or gradiation respectively. Similar increases, ranging from 30 ± 106% were detected following irradiation or udarabine treatment of a further four B-CLL isolates (not shown).
Apoptotic cells showing nuclear condensation were clearly identi®ed following¯udarabine treatment of B-CLL cells (Figure 9 ). However, cells showing necrotic features without evidence of nuclear condensation were also evident (Figure 9 ). Dying g-irradiated cells showed NA, no addition, D, +20 mM C 2 dihydroceramide, C, +20 mM C 2 ceramide, OA, +20 nM okadaic acid, Eto, +5 mM etoposide. Cells were incubated for the times indicated prior to extraction and caspase 3 assay. Bars indicate the range of duplicate determinations Figure 6 Western blot analysis for expression of bcl-2 and bax in B-CLL cells from 15 patients. The same ®lter was exposed sequentially to bcl-2 and bax antibodies. The percentage of dead cells observed following 6 h incubation with 20 mM C 2 ceramide is shown above each lane Figure 7 Eects of 20 mM sphingosine (Sph), 10 mM MAPP or 20 mM C 2 ceramide (Cer) on the viability of B-CLL cells. Viability was determined by trypan blue staining. Similar results were obtained in two additional experiments a predominantly non-apoptotic morphology in this experiment (Figure 9) .
The morphology of a further ®ve B-CLL isolates was analysed by light microscopy (Table 3) . Although both¯udarabine and g-radiation resulted in substantial and largely comparable killing of all of the isolates, the induction of apoptosis by these agents was highly variable. Apoptosis was almost undetectable in experiments 1 and 4, despite high rates of overall cell killing. A substantial proportion of apoptotic cells was only seen in experiment 3. Therefore, non-apoptotic killing may play a signi®cant role in the death of B-CLL cells following exposure to¯udarabine or gradiation. However, apoptotic pathways were functional in each of the isolates studied here, since 24 h treatment with okadaic acid resulted in the generation of 460% apoptotic cells in all cases (not shown). Since both¯udarabine and g-radiation elicit ceramide generation, it is possible, though not proven, that a proportion of these non-apoptotic deaths are triggered by ceramide.
Discussion
The data here show that C 2 ceramide, a molecular signal which induces apoptosis in leukaemia cell lines, induces necrotic death in freshly isolated normal and malignant B lymphocytes. The inability of ceramide to induce apoptosis in B-CLL is not due to a defective apoptotic pathway, since okadaic acid readily induced nuclear condensation and DNA fragmentation in a large proportion of cells. It is also unlikely that the necrotic mode of death induced by C 2 ceramide is the result of its breakdown to sphingosine. Furthermore, B-CLL killing was caspase independent whereas ceramide-induced death of HL60 cells was dependent on caspase activation. However, okadaic acid-induced apoptotic killing of B-CLL was also mediated by caspase activation, emphasizing that the apoptotic mechanism is indeed activable in these cells.
A possible overlap in mechanisms involved in the regulation of necrosis and apoptosis is suggested by the reported ability of bcl-2, bcl-X L and caspase inhibitors to block necrosis induced by chemically induced hypoxia (Shimizu et al., 1996) . However, ceramide killing of B-CLL cells from 15 patients failed to correlate with expression levels of bcl-2 or bax, suggesting that the cellular levels of these proteins did not modulate the killing of these cells by ceramide. The inability of the protein synthesis inhibitor cycloheximide to block killing of B-CLL cells by C 2 ceramide suggests that the induction of new gene expression, for example via the JNK/c-jun pathway (Sawai et al., 1995; Westwick et al., 1995) does not play a role in death induction in this context.
The dependence of C 2 ceramide action on the presence of a double bond in the sphingosine moiety argues that killing of B-lymphoid cells is the result of interaction of ceramide with a speci®c cellular target rather than by a non-speci®c mechanism. Peripheral blood T-lymphocytes, which are sensitive to nonapoptotic killing by C 2 ceramide, become refractory to killing by this lipid following mitogenic activation (Mengubas et al., in preparation) . This observation is consistent with the hypothesis that non-apoptotic Figure 8 Estimation of ceramide levels in B-CLL cells. Cells were untreated (C) or treated with 40 mM¯udarabine (F) or 7 Gy g-radiation (R). Lipids were analysed for ceramide content as described in Materials and methods. The radiolabelled ceramide-1-phosphate band is shown Cells were incubated for 20 h prior to processing for electron microscopic analysis Cell isolates from ®ve B-CLL patients were incubated with the indicated concentrations of¯udarabine or exposed to the indicated concentrations of¯udarabine or exposed to the indicated doses of g-radiation. Following 20 h incubation, the percentage of dead cells (D) was determined by trypan blue staining and the percentage of apoptotic cells (A) by morphological analysis killing by C 2 ceramide requires interaction with a speci®c target which is present in resting T-lymphocytes but whose expression is downregulated following mitogenic activation. Finally, the large variation in the rate of killing of dierent B-CLL isolates by C 2 ceramide is consistent with a variation in the expression of this putative target in dierent patients. The immediate biochemical target of ceramide which activates cell death has not been identi®ed (Susin et al., 1997a) . The data here suggest that this target couples to pathways which result in the activation of caspases in some cells, including the HL60 and Jurkat cell lines. However, this pathway may be defective in other cell types, including B-CLL cells and normal B and T lymphocytes, resulting in coupling of the ceramide target to non-apoptotic pathways. The induction by C 2 ceramide of a non-apoptotic form of death in Jurkat cells treated with a caspase inhibitor is also consistent with this hypothesis.
The killing of B-CLL cells by¯udarabine treatment has been reported to involve induction of apoptosis (Consoli et al., 1998) . However, we observed that B-CLL killing by¯udarabine occurs by both apoptotic and non-apoptotic mechanisms and that the relative contribution of each mode of killing shows marked patient-to-patient variation. Treatment of B-CLL cells with either¯udarabine or g-radiation resulted in clear increases in cell-associated ceramide levels. It is therefore possible, but not directly proven, that ceramide-mediated non-apoptotic death contributes to overall cell killing in this context. However, de®nitive proof of the role of ceramide in cytotoxic killing of B-CLL cells will require a speci®c inhibitor of ceramide generation.
The apoptotic mode of death induced by Fas ligation or by staurosporine has been shown to switch to necrosis following ATP depletion (Eguchi et al., 1997; Leist et al., 1997) . B-CLL cells contain approximately 300 pmol ATP/10 6 cells (DLO and RGW, unpublished) a level substantially lower than that reported for Jurkat cells (4.5 nmol/10 6 cells; Leist et al., 1997) . However, B-CLL cells are largely nonproliferating and substantially smaller than are Jurkat cells. Importantly, OA-induced killing of B-CLL proceeded via an apoptotic mechanism. It is therefore unlikely that low ATP levels underlies the induction of necrosis following treatment of B-CLL cells with C 2 ceramide,¯udarabine or g-radiation.
Direct pharmacological activation of the ceramide pathway has been proposed as a potential therapeutic option in the treatment of malignancy (HaimovitzFriedman et al., 1997) . We have shown for the ®rst time that freshly isolated human leukaemia cells are susceptible to killing by a synthetic ceramide analogue. Since B-CLL cannot be cured by conventional chemotherapy (Foon et al., 1990) , further investigation of lipid-mediated cell killing pathways may be warranted in this disease.
Materials and methods

Reagents
Tissue culture reagents were from Life Technologies, UK. Antibodies for Western blot detection of bcl-2 and bax were from Dako, UK and Santa Cruz, CA, USA respectively. C 2 -ceramide, C 2 -dihydroceramide, MAPP and diacylglycerol kinase were from Calbiochem, UK. Caspase substrates and inhibitors were from Aniti, UK. Okadaic acid and udarabine were from Sigma, UK. ZVADfmk was from Enzyme Systems Products, Dublin, CA, USA. Radiochemicals were purchased from Amersham International, UK.
Cell isolation
B-CLL cells and normal tonsillar lymphocytes were isolated by density gradient centrifugation and their purity established by cell-surface marker analysis as described (Panayiotidis et al., 1993) .
Incubation of cells with synthetic ceramide analogues
The wells of a 16-well tissue culture plate were pre-treated by overnight incubation with RPMI 1640 medium containing 20% foetal bovine serum and washed three times with RPMI medium alone. Cells were suspended in serum-free RPMI medium containing antibiotics. One millilitre aliquots were placed in the tissue culture wells. Synthetic ceramide analogues were prepared as 1 mM stock solutions in serumfree RPMI medium by sonication and added immediately to the cell suspensions giving ®nal concentrations of 20 mM.
Assessment of cell death and apoptosis induction
Cell killing was assessed by determining the percentage of cells permeable to 0.1% trypan blue (Cotter and Martin, 1996) . The standard error of the mean of triplicate determinations was 510%. Cell death was also assessed by determining the proportion of cells permeable to propidium iodide by FACScan analysis (Naito et al., 1997) . Cytospin preparations of cells were stained with MayGrunwald Giemsa. The proportion of apoptotic cells was determined by scoring for cells showing nuclear condensation and fragmentation (Cotter and Martin, 1996) . DNA fragmentation was determined by in situ labelling of cytospin preparations using terminal deoxynucleotidyl transferase and uoresceinated dUTP (TUNEL assay). The Apoptosis Detection Kit (Promega, Southampton, UK) was used following the manufacturer's instructions.
Apoptosis induction was also quanti®ed by determining the percentage of cells with a sub-diploid DNA content by FACScan analysis (Naito et al., 1997; Tay et al., 1996) .
Western blotting
Western blot analysis was carried out as described (Tay et al., 1996) . Equal loading and transfer of proteins was veri®ed by staining the transfer membrane with 0.1% Ponceau red.
Caspase assays
Caspase 3 activity was determined by quantifying the liberation of p-nitroanilide from the chromogenic substrate AcDEVDpNA as described . Control reactions contained 1 mM of the speci®c caspase 3 inhibitor AcDEVD-CHO.
Lipid extraction and quantitation of ceramide B-CLL cells were labelled overnight with 10 mCi mL 71 [2-3 H] glycerol. Following treatment of 5610 6 cells with cytotoxic drugs or radiation, lipids were extracted using CHCl 3 :methanol:HCl (Bose et al., 1995) . The extracts were dried and the lipids suspended in 0.5 N methanolic KOH. The 3 H-label in each sample was determined by scintillation counting. Samples were then incubated at 378C for 1 h to hydrolyze glycerolipids. Lipids were re-isolated and ceramide was determined by the diacylglycerol kinase assay (Bose et al., 1995) . A standard curve, constructed using known amounts of ceramide, was used to calculate the ceramide content of cell extracts. Results were normalized with respect to the recovery of total 3 H-labelled lipids.
